Vysioneer today announced it will showcase VBrain at the NVIDIA booth at the Radiological Society of North America (RSNA) 2019 conference to demonstrate how AI can be used to improve brain tumor care.
Vysioneer Inc. launched VBrain for clinical trials at National Taiwan University Hospital in Taipei in July 2019. The system was tested on more than 20 patients with brain metastasis, meningioma, and acoustic neuroma.
Vysioneer’s VBrain is a deep learning-based system that automatically contours brain tumors, including brain metastasis, meningioma, and acoustic neuroma, to support radiosurgery treatment planning.
Vysioneer is an oncology AI company headquartered in Cambridge, MA. Its FDA-cleared cloud-based platform uses machine learning for lesion-level precision to help pharma and clinicians identify treatments for cancer patients.
Founded in 2019, Vysioneer uses artificial intelligence and cloud services for cancer care. Its mission is to make cancer care more accurate, efficient, and globally accessible.
